News | Patient Positioning Radiation Therapy | August 30, 2019

Civco Highlights Universal Couchtop ProForm at ASTRO 2019

Couchtop allows direct access to central nervous system cancer patients for proton therapy

August 30, 2019 — Civco will display its Universal Couchtop ProForm Head & Neck Solution at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago.

The Universal Couchtop ProForm allows proton therapy centers direct access to effectively treat central nervous system (CNS) cancer patients. The extension is quick and easy to attach, and features a large 121.5 cm junction-free and artifact-free treatment area. The ProForm contains a homogeneous treatment area with soft gradient edges that reduce beam degradation. The couchtop accepts a thermoplastic mask with a smaller profile frame and pin similar to Civco’s Type-S system.

For more information: www.civco.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020

Shorter Radiotherapy Treatment Recommended for Bowel Cancer Patients During COVID-19

April 7, 2020 — An intern...

Eclipse v16 has received CE mark and is 510(k) pending

News | Proton Therapy | April 06, 2020

Varian Brings Machine Learning to Proton Treatment Planning

April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor

Artificial Intelligence Greatly Speeds Radiation Therapy Treatment Planning

The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new

Collaboration offers clinicians a personalized oncology solution that combines cutting-edge MRI-guided radiation therapy with a leading AI-driven EMR integration platform

News | Radiation Oncology | April 01, 2020

ViewRay and VieCure Announce Strategic Collaboration to Accelerate Adoption of Personalized Cancer Care

April 1, 2020 — ViewRay, Inc. announced a strategic collaboration

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020

A New Paper on the Pros and Cons of Radiotherapy

March 30, 2020 — Women undergoing radiotherapy for

A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

News | Prostate Cancer | March 30, 2020

Managing Prostate Cancer Patients During the COVID-19 Pandemic

March 30, 2020 — In the wake of the COVID-19 pan

Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020

High-resolution PET/CT Assesses Brain Stem Function in Patients with Hearing Impairment

March 26, 2020 — Novel, fully digital, high-resolution...

PSMA PET-CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning

News | Prostate Cancer | March 23, 2020

Prostate Cancer Study Finds Molecular Imaging Could Transform Management of Patients with Aggressive Cancer

March 23, 2020 — Results from a...

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals

News | Radiation Oncology | March 16, 2020

CDC Reports Cancer Death Rates Continue to Decline

March 16, 2020 — The Ann...

Reflexion eceived marketing clearance from the U.S. Food & Drug Administration (FDA) for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT) for its RefleXion X1 machine

News | Stereotactic Body Radiation Therapy (SBRT) | March 13, 2020

FDA Clearance Brings RefleXion Closer to Expanding Cancer Treatment Market

March 13, 2020 — RefleXion Medical, a therapeutic oncology company pioneering